# A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

> **NCT06452160** · PHASE1 · RECRUITING · sponsor: **BridGene Biosciences Inc.** · enrollment: 103 (estimated)

## Conditions studied

- Mesothelioma
- Epithelioid Hemangioendothelioma(EHE)
- Solid Tumor

## Interventions

- **DRUG:** BGC515

## Key facts

- **NCT ID:** NCT06452160
- **Lead sponsor:** BridGene Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-27
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 103 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06452160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06452160, "A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06452160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*